BeiGene's receivables is $940M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
BeiGene (BGNE) currently reports a receivables of $940M as of March 2026. That compares with $720M in the prior-year period — up 30.8% year over year. Use the charts on this page to explore BeiGene's receivables history and peer comparisons.
BeiGene's receivables increased from $720M to $940M — a 30.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
BeiGene reported $940M in receivables as of March 2026. That compares with $720M in the prior-year period — up 30.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $940M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BeiGene, and consider following BGNE for alerts when major investors trade the stock.
BeiGene is classified in the Healthcare sector. On receivables, it currently shows $940M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BGNE with unrelated industries.